HK1257240A1 - Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine - Google Patents

Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine

Info

Publication number
HK1257240A1
HK1257240A1 HK18116276.1A HK18116276A HK1257240A1 HK 1257240 A1 HK1257240 A1 HK 1257240A1 HK 18116276 A HK18116276 A HK 18116276A HK 1257240 A1 HK1257240 A1 HK 1257240A1
Authority
HK
Hong Kong
Prior art keywords
medicine
preventing
tissue injury
injury caused
treating tissue
Prior art date
Application number
HK18116276.1A
Other languages
Chinese (zh)
Inventor
李季男
Original Assignee
深圳瑞健生命科學研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞健生命科學研究院有限公司 filed Critical 深圳瑞健生命科學研究院有限公司
Publication of HK1257240A1 publication Critical patent/HK1257240A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
HK18116276.1A 2016-12-15 2018-12-19 Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine HK1257240A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611162237 2016-12-15
CN201611161347 2016-12-15

Publications (1)

Publication Number Publication Date
HK1257240A1 true HK1257240A1 (en) 2019-10-18

Family

ID=62656680

Family Applications (7)

Application Number Title Priority Date Filing Date
HK18116276.1A HK1257240A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine
HK18116273.4A HK1257237A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating fatty liver and use of medicine
HK18116275.2A HK1257239A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating obesity and use of the medicine
HK18116269.0A HK1257233A1 (en) 2016-12-15 2018-12-19 Medicine for preventing atherosclerosis and complications of atherosclerosis and use of medicine
HK18116270.7A HK1257234A1 (en) 2016-12-15 2018-12-19 Medicine for treating coronary atherosclerosis as well as complications of coronary atherosclerosis and use of the medicine
HK18116272.5A HK1257236A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating hyperlipemia diseases and use of the medicine
HK18116702.5A HK1257583A1 (en) 2016-12-15 2018-12-28 Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine

Family Applications After (6)

Application Number Title Priority Date Filing Date
HK18116273.4A HK1257237A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating fatty liver and use of medicine
HK18116275.2A HK1257239A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating obesity and use of the medicine
HK18116269.0A HK1257233A1 (en) 2016-12-15 2018-12-19 Medicine for preventing atherosclerosis and complications of atherosclerosis and use of medicine
HK18116270.7A HK1257234A1 (en) 2016-12-15 2018-12-19 Medicine for treating coronary atherosclerosis as well as complications of coronary atherosclerosis and use of the medicine
HK18116272.5A HK1257236A1 (en) 2016-12-15 2018-12-19 Medicine for preventing and treating hyperlipemia diseases and use of the medicine
HK18116702.5A HK1257583A1 (en) 2016-12-15 2018-12-28 Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine

Country Status (2)

Country Link
CN (8) CN108210904A (en)
HK (7) HK1257240A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108671226A (en) * 2018-08-08 2018-10-19 广州铭康生物工程有限公司 The drug and application thereof of effective therapeutic community ductus venosus complication
CN110093412A (en) * 2019-03-29 2019-08-06 南方医科大学南方医院 For the molecular marker UGP2 of diagnosing atherosclerotic and application
CN111100928A (en) * 2020-01-09 2020-05-05 武汉科技大学 Atherosclerosis biomarker and atherosclerosis diagnosis kit
CA3169325A1 (en) * 2020-02-26 2021-09-02 Jinan Li Method and drug for preventing and treating abnormal blood pressure condition
CN112305120B (en) * 2020-10-30 2022-02-08 河北医科大学第二医院 Application of metabolite in atherosclerotic cerebral infarction

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408431A (en) * 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 Gene engineering medicine for curing diseases relative to vascularization
WO2003066842A2 (en) * 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Method for producing recombinant proteins in micro-organisms
AU2003301809A1 (en) * 2002-05-13 2004-06-07 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
CN101396559A (en) * 2002-12-06 2009-04-01 法布罗根股份有限公司 Fat regulation
ES2325071T3 (en) * 2002-12-10 2009-08-25 Wyeth DERIVATIVES OF INDOL-OXO-ACETILAMINOACETIC ACID REPLACED AS INHIBITORS OF THE PLASMINOGEN-1 ACTIVATOR INHIBITOR (PAI-1).
WO2005026127A1 (en) * 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. Plasminogen activator inhibitor-1 inhibitor
ES2349555T3 (en) * 2004-04-22 2011-01-05 Talecris Biotherapeutics, Inc. MODIFIED PLASMINE RECOMBINATELY.
WO2006095713A1 (en) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. Inhibitor of plasminogen activator inhibitor-1
US20090123582A1 (en) * 2006-03-24 2009-05-14 Akiko Kuwahara Ameliorating Agent for Metabolic Syndrome
CN101563100B (en) * 2006-08-28 2013-08-07 李季男 Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
CN101686994B (en) * 2006-10-20 2013-05-01 陶氏环球技术公司 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
KR20100097113A (en) * 2007-10-23 2010-09-02 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 Pai-1 production inhibitor
US20090239868A1 (en) * 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
RU2564131C2 (en) * 2009-07-10 2015-09-27 ТромбоДженикс НВ Versions of plasminogen and plasmin
EP3251686A1 (en) * 2009-08-12 2017-12-06 Cornell University Methods for preventing or treating metabolic syndrome
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
EP2661493B1 (en) * 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
KR20140010126A (en) * 2011-03-03 2014-01-23 터서스 파마수티칼 엘엘씨 Compositions and methods comprising c16:1n7-palmitoleate
CN102188699A (en) * 2011-05-06 2011-09-21 南京农业大学 Pharmaceutical composition for treating atherosclerosis, and preparation method and application thereof
WO2013024074A1 (en) * 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN102532326B (en) * 2011-11-18 2017-06-09 南京大学 A kind of human fiber plasminogen Kringle 5 variant of cancer target and its application
TN2016000048A1 (en) * 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US20160199466A1 (en) * 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis

Also Published As

Publication number Publication date
HK1257583A1 (en) 2019-10-25
HK1257237A1 (en) 2019-10-18
CN108210902A (en) 2018-06-29
HK1257233A1 (en) 2019-10-18
CN108210900A (en) 2018-06-29
CN108210904A (en) 2018-06-29
CN108210906A (en) 2018-06-29
HK1257236A1 (en) 2019-10-18
CN108210914A (en) 2018-06-29
CN108210896A (en) 2018-06-29
HK1257239A1 (en) 2019-10-18
CN108210895A (en) 2018-06-29
CN108210898A (en) 2018-06-29
HK1257234A1 (en) 2019-10-18

Similar Documents

Publication Publication Date Title
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL298689B1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
HK1257240A1 (en) Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine
HK1257321A1 (en) Histotripsy therapy systems and methods for the treatment of brain tissue
HK1256721A1 (en) Compounds and compositions for the treatment of ocular disorders
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
HK1257585A1 (en) Medicine for preventing and treating skin fibrosis and use of the medicine
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
IL272097A (en) Compounds for the prevention and treatment of medical disorders and uses thereof
IL269698B (en) Methods of preventing or treating ophthalmic diseases
EP3723742C0 (en) Use of fluoroethylnormemantine for the prevention and treatment of anxiety
IL248935A0 (en) Diagnostic test and treatment/prevention of alzheimer's disease
HK1257238A1 (en) Medicine for preventing and treating lipid kidney injury and use of the medicine
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
HK1257590A1 (en) Medicine for preventing and treating medicinal kidney injury and the use of the medicine
ZA201807692B (en) New use of product for skin treatment
IL256919A (en) Pharmaceutical compositions useful for the treatment of tissue injury
IL251135A (en) Method for the synthesis of hydroxy-triglycerides and use thereof for the prevention and treatment of diseases
PT3191112T (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation
IL259381B (en) Mirabegron for the treatment of retinal diseases
RS65225B1 (en) Medicament for the treatment and/or prevention of endometriosis
GB201604359D0 (en) Treatment of tissue disorders
ZA201904327B (en) Treatment of skin conditions
IL274132A (en) Treatment of skin disorders